Aigen Investment Management LP Boosts Position in Stryker Corporation $SYK

Aigen Investment Management LP lifted its stake in shares of Stryker Corporation (NYSE:SYK) by 188.2% during the 4th quarter, Holdings Channel reports. The fund owned 3,375 shares of the medical technology company’s stock after buying an additional 2,204 shares during the quarter. Aigen Investment Management LP’s holdings in Stryker were worth $1,186,000 at the end of the most recent quarter.

Other institutional investors have also modified their holdings of the company. Czech National Bank raised its holdings in Stryker by 3.9% in the 4th quarter. Czech National Bank now owns 90,755 shares of the medical technology company’s stock valued at $31,898,000 after buying an additional 3,366 shares during the period. Davis R M Inc. grew its position in Stryker by 1.8% in the 3rd quarter. Davis R M Inc. now owns 138,732 shares of the medical technology company’s stock valued at $51,285,000 after acquiring an additional 2,512 shares in the last quarter. Kepler Cheuvreux Suisse SA acquired a new position in Stryker in the 3rd quarter valued at about $27,952,000. Daymark Wealth Partners LLC grew its position in Stryker by 436.0% in the 4th quarter. Daymark Wealth Partners LLC now owns 45,863 shares of the medical technology company’s stock valued at $16,119,000 after acquiring an additional 37,307 shares in the last quarter. Finally, Varma Mutual Pension Insurance Co grew its position in Stryker by 10.5% in the 4th quarter. Varma Mutual Pension Insurance Co now owns 53,610 shares of the medical technology company’s stock valued at $18,842,000 after acquiring an additional 5,100 shares in the last quarter. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Stryker Stock Performance

Shares of Stryker stock opened at $312.14 on Friday. The business has a 50-day simple moving average of $316.40 and a 200-day simple moving average of $343.97. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.25 and a current ratio of 2.11. The company has a market cap of $119.66 billion, a PE ratio of 36.13, a P/E/G ratio of 1.97 and a beta of 0.78. Stryker Corporation has a one year low of $281.00 and a one year high of $404.87.

Stryker (NYSE:SYK) last announced its quarterly earnings results on Thursday, April 30th. The medical technology company reported $2.60 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.98 by ($0.38). The business had revenue of $6.02 billion during the quarter, compared to analyst estimates of $6.34 billion. Stryker had a net margin of 13.20% and a return on equity of 23.42%. The business’s revenue for the quarter was up 2.6% compared to the same quarter last year. During the same period last year, the company earned $2.84 earnings per share. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. On average, equities research analysts forecast that Stryker Corporation will post 14.98 EPS for the current fiscal year.

Stryker Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, July 31st. Investors of record on Tuesday, June 30th will be issued a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a yield of 1.1%. The ex-dividend date of this dividend is Tuesday, June 30th. Stryker’s dividend payout ratio is 40.74%.

Insider Activity at Stryker

In other Stryker news, VP M Kathryn Fink sold 5,220 shares of the business’s stock in a transaction that occurred on Monday, May 11th. The stock was sold at an average price of $283.85, for a total value of $1,481,697.00. Following the completion of the sale, the vice president owned 13,137 shares in the company, valued at approximately $3,728,937.45. The trade was a 28.44% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, VP Robert S. Fletcher sold 4,544 shares of the business’s stock in a transaction that occurred on Thursday, May 28th. The shares were sold at an average price of $306.87, for a total value of $1,394,417.28. Following the completion of the sale, the vice president owned 10,582 shares of the company’s stock, valued at approximately $3,247,298.34. This represents a 30.04% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 323,264 shares of company stock valued at $100,659,489 over the last three months. 4.60% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on the company. Sanford C. Bernstein set a $410.00 target price on Stryker in a research report on Friday, May 1st. Citigroup dropped their target price on Stryker from $420.00 to $385.00 and set a “buy” rating for the company in a research report on Tuesday, April 7th. The Goldman Sachs Group reaffirmed a “neutral” rating and issued a $361.00 target price on shares of Stryker in a research report on Friday, May 1st. Barclays dropped their target price on Stryker from $469.00 to $394.00 and set an “overweight” rating for the company in a research report on Monday, May 4th. Finally, JPMorgan Chase & Co. dropped their target price on Stryker from $445.00 to $400.00 and set an “overweight” rating for the company in a research report on Friday, May 1st. Sixteen analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. According to MarketBeat, Stryker currently has an average rating of “Moderate Buy” and an average target price of $395.33.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.